Articles related to RESEARCH & CLINICAL TRIALS

Treatment with gantenerumab for approximately eight years reduced the risk of developing symptoms from essentially 100% to about 50% in participants with genetic mutations causing early-onset Alzheimer’s.

In an intention-to-treat analysis, 4:3 IMF showed greater reductions in weight than DCR at 12 months (mean difference, 2.89 kg [95% CI, 5.65 to 0.14 kg]; P = 0.040).

Rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to those for low-dose aspirin, whereas rates were higher for rivaroxaban.

This study demonstrated that luteolin, a natural antioxidant, can suppress hair graying in model mice. Our findings suggest that luteolin could be a viable candidate for developing therapeutic interventions aimed at maintaining original hair color.

“…three drugs were associated with more negative or failed efficacy trials than positive ones…”

Results of multiple clinical trials demonstrate that SYMBRAVO can provide rapid and long-lasting freedom from migraine pain, whether treatment is taken early in the attack while the pain is mild, or later in the attack when the pain may be severe.